vs

Side-by-side financial comparison of California Resources Corp (CRC) and DENTSPLY SIRONA Inc. (XRAY). Click either name above to swap in a different company.

DENTSPLY SIRONA Inc. is the larger business by last-quarter revenue ($961.0M vs $679.0M, roughly 1.4× California Resources Corp). California Resources Corp runs the higher net margin — 1.8% vs -15.2%, a 17.0% gap on every dollar of revenue. On growth, DENTSPLY SIRONA Inc. posted the faster year-over-year revenue change (6.2% vs -17.8%). California Resources Corp produced more free cash flow last quarter ($115.0M vs $60.0M). Over the past eight quarters, California Resources Corp's revenue compounded faster (25.8% CAGR vs 0.4%).

California Resources Corporation is an American energy corporation engaged in hydrocarbon exploration in California. It is organized in Delaware and headquartered in Long Beach, California. Its mineral acreage holdings in California constitute the largest privately held position in the state.

Dentsply Sirona Inc. is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries. It has factories in 21 countries. The present company is largely the result of a merger in 1993 in which Gendex Corporation acquired Dentsply International Inc. for $590 million.

CRC vs XRAY — Head-to-Head

Bigger by revenue
XRAY
XRAY
1.4× larger
XRAY
$961.0M
$679.0M
CRC
Growing faster (revenue YoY)
XRAY
XRAY
+24.0% gap
XRAY
6.2%
-17.8%
CRC
Higher net margin
CRC
CRC
17.0% more per $
CRC
1.8%
-15.2%
XRAY
More free cash flow
CRC
CRC
$55.0M more FCF
CRC
$115.0M
$60.0M
XRAY
Faster 2-yr revenue CAGR
CRC
CRC
Annualised
CRC
25.8%
0.4%
XRAY

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CRC
CRC
XRAY
XRAY
Revenue
$679.0M
$961.0M
Net Profit
$12.0M
$-146.0M
Gross Margin
46.1%
Operating Margin
6.9%
-14.5%
Net Margin
1.8%
-15.2%
Revenue YoY
-17.8%
6.2%
Net Profit YoY
-63.6%
66.0%
EPS (diluted)
$0.21
$-0.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CRC
CRC
XRAY
XRAY
Q4 25
$679.0M
$961.0M
Q3 25
$715.0M
$904.0M
Q2 25
$702.0M
$936.0M
Q1 25
$814.0M
$879.0M
Q4 24
$826.0M
$905.0M
Q3 24
$870.0M
$951.0M
Q2 24
$412.0M
$984.0M
Q1 24
$429.0M
$953.0M
Net Profit
CRC
CRC
XRAY
XRAY
Q4 25
$12.0M
$-146.0M
Q3 25
$64.0M
$-427.0M
Q2 25
$172.0M
$-45.0M
Q1 25
$115.0M
$20.0M
Q4 24
$33.0M
$-430.0M
Q3 24
$345.0M
$-494.0M
Q2 24
$8.0M
$-4.0M
Q1 24
$-10.0M
$18.0M
Gross Margin
CRC
CRC
XRAY
XRAY
Q4 25
46.1%
Q3 25
48.8%
Q2 25
52.4%
Q1 25
53.0%
Q4 24
49.3%
Q3 24
52.1%
Q2 24
51.9%
Q1 24
53.1%
Operating Margin
CRC
CRC
XRAY
XRAY
Q4 25
6.9%
-14.5%
Q3 25
13.7%
-24.1%
Q2 25
38.0%
-13.7%
Q1 25
22.9%
7.2%
Q4 24
8.2%
-56.2%
Q3 24
59.5%
-48.6%
Q2 24
9.2%
5.1%
Q1 24
-0.9%
4.4%
Net Margin
CRC
CRC
XRAY
XRAY
Q4 25
1.8%
-15.2%
Q3 25
9.0%
-47.2%
Q2 25
24.5%
-4.8%
Q1 25
14.1%
2.3%
Q4 24
4.0%
-47.5%
Q3 24
39.7%
-51.9%
Q2 24
1.9%
-0.4%
Q1 24
-2.3%
1.9%
EPS (diluted)
CRC
CRC
XRAY
XRAY
Q4 25
$0.21
$-0.74
Q3 25
$0.76
$-2.14
Q2 25
$1.92
$-0.22
Q1 25
$1.26
$0.10
Q4 24
$0.87
$-2.09
Q3 24
$3.78
$-2.46
Q2 24
$0.11
$-0.02
Q1 24
$-0.14
$0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CRC
CRC
XRAY
XRAY
Cash + ST InvestmentsLiquidity on hand
$132.0M
$326.0M
Total DebtLower is stronger
$2.3B
Stockholders' EquityBook value
$3.7B
$1.3B
Total Assets
$7.4B
$5.4B
Debt / EquityLower = less leverage
1.70×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CRC
CRC
XRAY
XRAY
Q4 25
$132.0M
$326.0M
Q3 25
$196.0M
$363.0M
Q2 25
$72.0M
$359.0M
Q1 25
$214.0M
$398.0M
Q4 24
$372.0M
$272.0M
Q3 24
$241.0M
$296.0M
Q2 24
$1.0B
$279.0M
Q1 24
$403.0M
$291.0M
Total Debt
CRC
CRC
XRAY
XRAY
Q4 25
$2.3B
Q3 25
$1.0B
Q2 25
$1.0B
Q1 25
$1.0B
Q4 24
$1.1B
$1.7B
Q3 24
$1.1B
Q2 24
$1.2B
Q1 24
$541.0M
Stockholders' Equity
CRC
CRC
XRAY
XRAY
Q4 25
$3.7B
$1.3B
Q3 25
$3.4B
$1.5B
Q2 25
$3.4B
$2.0B
Q1 25
$3.5B
$2.0B
Q4 24
$3.5B
$1.9B
Q3 24
$3.5B
$2.5B
Q2 24
$2.1B
$3.1B
Q1 24
$2.1B
$3.3B
Total Assets
CRC
CRC
XRAY
XRAY
Q4 25
$7.4B
$5.4B
Q3 25
$6.8B
$5.7B
Q2 25
$6.7B
$6.1B
Q1 25
$6.8B
$6.0B
Q4 24
$7.1B
$5.8B
Q3 24
$7.1B
$6.6B
Q2 24
$4.5B
$6.9B
Q1 24
$3.9B
$7.1B
Debt / Equity
CRC
CRC
XRAY
XRAY
Q4 25
1.70×
Q3 25
0.29×
Q2 25
0.30×
Q1 25
0.29×
Q4 24
0.32×
0.90×
Q3 24
0.32×
Q2 24
0.57×
Q1 24
0.26×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CRC
CRC
XRAY
XRAY
Operating Cash FlowLast quarter
$235.0M
$101.0M
Free Cash FlowOCF − Capex
$115.0M
$60.0M
FCF MarginFCF / Revenue
16.9%
6.2%
Capex IntensityCapex / Revenue
17.7%
4.3%
Cash ConversionOCF / Net Profit
19.58×
TTM Free Cash FlowTrailing 4 quarters
$543.0M
$104.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CRC
CRC
XRAY
XRAY
Q4 25
$235.0M
$101.0M
Q3 25
$279.0M
$79.0M
Q2 25
$165.0M
$48.0M
Q1 25
$186.0M
$7.0M
Q4 24
$206.0M
$87.0M
Q3 24
$220.0M
$141.0M
Q2 24
$97.0M
$208.0M
Q1 24
$87.0M
$25.0M
Free Cash Flow
CRC
CRC
XRAY
XRAY
Q4 25
$115.0M
$60.0M
Q3 25
$188.0M
$40.0M
Q2 25
$109.0M
$16.0M
Q1 25
$131.0M
$-12.0M
Q4 24
$118.0M
$36.0M
Q3 24
$141.0M
$98.0M
Q2 24
$63.0M
$156.0M
Q1 24
$33.0M
$-9.0M
FCF Margin
CRC
CRC
XRAY
XRAY
Q4 25
16.9%
6.2%
Q3 25
26.3%
4.4%
Q2 25
15.5%
1.7%
Q1 25
16.1%
-1.4%
Q4 24
14.3%
4.0%
Q3 24
16.2%
10.3%
Q2 24
15.3%
15.9%
Q1 24
7.7%
-0.9%
Capex Intensity
CRC
CRC
XRAY
XRAY
Q4 25
17.7%
4.3%
Q3 25
12.7%
4.3%
Q2 25
8.0%
3.4%
Q1 25
6.8%
2.2%
Q4 24
10.7%
5.6%
Q3 24
9.1%
4.5%
Q2 24
8.3%
5.3%
Q1 24
12.6%
3.6%
Cash Conversion
CRC
CRC
XRAY
XRAY
Q4 25
19.58×
Q3 25
4.36×
Q2 25
0.96×
Q1 25
1.62×
0.35×
Q4 24
6.24×
Q3 24
0.64×
Q2 24
12.13×
Q1 24
1.39×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CRC
CRC

Oil And Natural Gas Segment$645.0M95%
Natural Gas Production$26.0M4%
Other$7.0M1%

XRAY
XRAY

Essential Dental Solutions$372.0M39%
Equipment And Instruments$160.0M17%
Implants And Prosthetics$150.0M16%
CADCAM$139.0M14%
Wellspect Healthcare$88.0M9%
Orthodontics$52.0M5%

Related Comparisons